GlassScriptPhysician profile
William Alan Paul
NPI 1407831589
$6,751.18
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,222 · 2020: $1,781 · 2021: $2,054 · 2022: $694.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,544.42 | 2019-2022 | |
| Abbvie INC. | $818.23 | 2019-2022 | |
| Glaxosmithkline, LLC. | $528.75 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $503.37 | 2019-2022 | |
| Janssen Biotech, INC. | $481.26 | 2019-2022 | |
| Pfizer INC. | $422.50 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $351.50 | 2019-2021 | |
| Ucb, INC. | $290.18 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.07 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $252.98 | 2019 | |
| Radius Health, INC. | $228.55 | 2019-2021 | |
| Aurinia Pharma U.S., INC. | $170.35 | 2021-2022 | |
| Genentech USA, INC. | $144.28 | 2019-2021 | |
| Pacira Therapeutics, INC. | $143.71 | 2019-2021 | |
| Lilly USA, LLC | $122.70 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medexus Pharma, INC. | $115.61 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $85.61 | 2019 | |
| Celgene Corporation | $75.53 | 2019 | |
| Horizon Therapeutics Plc | $68.13 | 2019-2022 | |
| Ultragenyx Pharmaceutical INC. | $42.55 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $33.23 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $31.66 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $21.44 | 2022 | |
| Ani Pharmaceuticals, INC. | $20.57 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Paul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.